Last updated: April 27, 2026
Who Supplies Benazepril Hydrochloride and Hydrochlorothiazide (API) for Generic and Combination Products?
What are the core API supply inputs for benazepril HCl / hydrochlorothiazide fixed-dose products?
Most fixed-dose products combine two separate APIs:
- Benazepril hydrochloride (API): ACE inhibitor.
- Hydrochlorothiazide (API): thiazide diuretic.
Commercial supply for these APIs typically comes from:
- Primary API manufacturers (commercial synthesis)
- Secondary suppliers (API traders and distributors with packaged/qualified supply)
- Formulation-scale suppliers (API supplied under DMF/CEP framework for abbreviated applications)
Which organizations supply these APIs in the market?
The global market for benazepril HCl and hydrochlorothiazide includes the following supplier types and named entities commonly active in API supply and/or combination manufacturing pipelines.
Primary API manufacturers and large-scale API suppliers (commonly seen in dossiers and commercial supply chains)
- Hetero Drugs (API and formulations across cardiometabolic lines)
- Aurobindo Pharma (API manufacturing and branded/generic supply)
- Cipla (API integration and contract/outsourced sourcing network)
- Mylan (Viatris) (generic and API sourcing footprint)
- Sandoz (generic and API supply chain presence)
- Siegfried (API and complex manufacturing capability; used in outsourcing networks)
- Teva (API/formulation sourcing footprint)
Specialty API and contract manufacturing networks used for ACE inhibitor and thiazide API supply
- Zydus Lifesciences
- Sun Pharmaceutical Industries
- Dr. Reddy’s Laboratories
- Lupin
- Torrent Pharmaceuticals
- Cadila Pharmaceuticals (Zydus Group)
Where market tracking is most actionable (regulatory and compliance sources)
To identify current, qualify-able suppliers for a specific benazepril HCl / hydrochlorothiazide strength and dossier type, market participants typically cross-check:
- US FDA DMF holder lists
- CEP holder lists (EDQM)
- EU GMP inspections and official manufacturer listings
- Vendor qualification packages used by generic manufacturers
What supplier classification should procurement use for risk control?
For benazepril HCl / hydrochlorothiazide, procurement should treat supply as two separate critical inputs with distinct quality systems and batch release documentation.
| Supply input |
Typical procurement route |
Key documents procurement expects |
| Benazepril hydrochloride API |
DMF or CEP-backed API supply |
DMF correspondence or CEP certificate, CoA, impurity profile |
| Hydrochlorothiazide API |
DMF or CEP-backed API supply |
CEP/DMF support, CoA, residual solvents and impurities |
| Fixed-dose combination drug product |
Contract manufacturing with qualified APIs |
Finished product CoA, stability protocol, regulatory alignment |
Which supplier set best fits US ANDA commercialization workflows?
For US ANDAs of benazepril HCl and hydrochlorothiazide combination products, buyers usually prioritize suppliers that can support:
- DMF-backed supply (active DMF holder or authorized RLD-compatible routes)
- Batch-level traceability aligned with ANDA CMC expectations
- Consistent impurity control across multiple campaigns
The most operationally useful supplier set in this category is typically:
- Large generic manufacturers with integrated API supply chains (Aurobindo, Teva, Sandoz, Viatris)
- Large API manufacturers with DMF coverage (Dr. Reddy’s, Lupin, Sun Pharma, Zydus)
- Contract manufacturing ecosystems used for scaling and packaging under validated GMP
How to map suppliers by dossier support (DMF/CEP logic)
Procurement teams usually build a short list via:
- DMF holders for benazepril hydrochloride API (USP/ICH impurity control alignment)
- DMF holders for hydrochlorothiazide API
- Either shared or independent supplier qualification depending on the finished-dose manufacturer’s system
- Compatibility with the buyer’s regulatory strategy (US ANDA vs EU generics)
What strengths and commercial packaging considerations impact supplier choice?
Supply chain decisions are tied to the specific marketed strengths and dosage forms.
| Common fixed-dose strength pattern |
Procurement impact |
| Benazepril HCl 10/20/40 mg + Hydrochlorothiazide (12.5/25 mg) |
Requires tight API assay and impurity specifications because small HCTZ dose units amplify assay drift risk |
| Tablets only (most fixed-dose formats) |
Excipient compatibility and blend uniformity affect which suppliers can reliably deliver consistent API particle and bulk properties |
Supplier shortlist logic used by formulators (practical)
For benazepril HCl / hydrochlorothiazide, formulators typically qualify suppliers based on:
- Assay range and impurity limits consistency
- Particle size/bulk density behavior for blend uniformity in tablets
- Source consistency across campaigns for stability and dissolution reproducibility
- Ability to provide audit-ready GMP documentation
What procurement outcomes these supplier groups deliver
| Supplier group |
Procurement advantage |
Procurement risk |
| Integrated large generics (Aurobindo, Teva, Sandoz, Viatris) |
Regulatory document readiness and supply continuity |
Higher pricing tiers, allocation constraints |
| Major Indian API manufacturing platforms (Lupin, Dr. Reddy’s, Sun, Zydus) |
Strong API scale and multiple campaign history |
Variation risk if manufacturing changes without full notification |
| Contract manufacturing ecosystem (Siegfried-type) |
Formulation and packaging process alignment |
Requires strict change control from API to finished dose |
What named supplier categories should you prioritize for immediate outreach
Given the API nature of benazepril hydrochloride and hydrochlorothiazide, the fastest path is outreach to:
- DMF-capable API manufacturers for each API separately
- API distributors that can deliver qualified, batch-tested supply under GMP with full traceability
- Finish-dose CMOs that already source these APIs and can qualify supply faster under their established QMS
Key Takeaways
- Benazepril hydrochloride and hydrochlorothiazide fixed-dose products depend on two separate API supply lanes, each typically sourced through DMF/CEP-supported manufacturers.
- The most actionable supplier set for US/EU generic commercialization is dominated by large integrated generic and major Indian API manufacturers (e.g., Aurobindo, Teva, Sandoz, Viatris, Dr. Reddy’s, Lupin, Sun Pharma, Zydus).
- Procurement should qualify suppliers by regulatory support (DMF/CEP), impurity and assay consistency, and tablet manufacturability (bulk properties, blend uniformity).
- Supplier selection is strengthened when procurement aligns the API source capability with the finished-dose manufacturer’s QMS and change-control model.
FAQs
1) Are benazepril hydrochloride and hydrochlorothiazide usually purchased from the same supplier?
They are often purchased from different suppliers unless the finished-dose manufacturer has a dual-API procurement arrangement. Quality control and DMF/CEP alignment drive the final decision.
2) What matters most for API qualification in tablets?
API assay, impurity profile, and physical properties that affect blend uniformity and dissolution (bulk density and particle behavior) drive qualification.
3) Do DMF and CEP support affect supplier selection?
Yes. In generic workflows, DMF/CEP-backed suppliers reduce regulatory friction and speed documentation readiness.
4) Can API distributors supply these APIs directly?
Yes, but qualification depends on whether the distributor can provide audit-ready GMP documentation, CoA traceability, and batch-specific impurity data.
5) How do supplier changes affect stability and bioequivalence risk?
API source changes can change impurity distribution and physical properties. This can impact dissolution and stability, so change control is critical in fixed-dose combinations.
References
- European Directorate for the Quality of Medicines (EDQM). Public CEP information (CEP certificates database).
- U.S. Food and Drug Administration (FDA). Drug Master File (DMF) listings and DMF-related regulatory materials.
